Medco, Quest Diagnostics Personalized Medicine Study Yields Additional Clues about Patient Engagement
FRANKLIN LAKES, N.J. and MONTREAL, Oct. 13, 2011 /PRNewswire/ -- The Medco Research Institute®, the research subsidiary of Medco Health Solutions, Inc. (NYSE: MHS ), and Quest Diagnostics (NYSE: DGX ) announced their study showed a statistically significant increase in adherence to statin therapy over six months in patients receiving kinesin-like protein 6 (KIF6) gene testing, compared with those who did not. The AKROBATS (Additional KIF6 Risk Offers Better Adherence to Statins) trial is the first "real-world" study designed to prospectively evaluate the impact of the KIF6 gene testing on patient adherence to cholesterol-lowering drugs. Full data results are expected to be published or presented at an upcoming scientific congress by spring 2012.
The AKROBATS trial also is revealing new information on patient attitudes and perceptions about personalized medicine, including the factors that influence acceptance of gene testing for statin therapy and their overall preferences for participating in studies. The results, presented today at the 61st American Society of Human Genetics conference in Montreal, Canada, showed that age, therapy prescribed, logistical considerations, and health beliefs may influence the decision to decline or accept genetic testing in clinical trials, researchers said. A slight majority of participants entered the study because of the perceived value related to treating their condition.
"While we know about the important effect that statin therapy adherence has on the prevention of a heart attack, stroke or other cardiovascular problems, we now have the first data supporting a role for genetic testing as means of improving adherence for this widely-used class of drugs," said